, Volume 39, Issue 6, pp 549–554 | Cite as

Combination therapy with an aminoglycoside for Staphylococcus aureus endocarditis and/or persistent bacteremia is associated with a decreased rate of recurrent bacteremia: a cohort study

  • T. L. Lemonovich
  • K. Haynes
  • E. Lautenbach
  • V. K. Amorosa
Brief Report



Although limited data exist on the efficacy and potential risk of synergistic aminoglycoside therapy for persistent Staphylococcus aureus bacteremia and endocarditis, aminoglycosides are frequently used in clinical practice.


As our study population, we included subjects fulfilling the modified Duke criteria for S. aureus endocarditis and/or having greater than 72 h of S. aureus bacteremia. Among these subjects, we compared patients who did and did not receive aminoglycoside therapy for their S. aureus bloodstream infection. These groups were compared for the primary outcome of recurrent bacteremia, as well as for the duration of bacteremia, mortality, complication rate, and incident renal failure.


Eighty-seven subjects fulfilled the inclusion criteria. Of these, 49 received aminoglycoside therapy, whereas 38 did not. There were no significant differences in the baseline characteristics when comparing groups who did or did not receive aminoglycoside therapy. Four (8.2%) subjects treated with aminoglycoside therapy experienced recurrent bacteremia versus nine (23.7%) who did not receive aminoglycoside therapy [relative risk and 95% confidence interval [RR (95%CI)] = 0.51 (0.22−1.17), p = 0.04]. In multivariable analyses, aminoglycoside use remained significantly associated with a decrease in recurrent bacteremia [adjusted odds ratio (OR) (95%CI) = 0.26 (0.07−0.98), p = 0.046]. No significant differences were seen between groups treated with and without an aminoglycoside in terms of the 6-month all-cause mortality (51.0 vs. 42.1%, p = 0.41), complication rate (71.4 vs. 73.7%, p = 0.82), or incident renal failure (54.5 vs. 46.9%, p = 0.54).


The use of combination therapy with an aminoglycoside in persistent S. aureus bacteremia and/or endocarditis may be associated with a lower rate of recurrent bacteremia without significant differences in the incident renal failure.


  1. 1.
    Shurland S, Zhan M, Bradham DD, et al. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol. 2007;28:273–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Graham JC, Gould FK. Role of aminoglycosides in the treatment of bacterial endocarditis. J Antimicrob Chemother. 2002;49:437–44.PubMedCrossRefGoogle Scholar
  3. 3.
    Petti CA, Fowler VG Jr. Staphylococcus aureus bacteremia and endocarditis. Infect Dis Clin North Am 2002;16:413–435, x–xi.PubMedCrossRefGoogle Scholar
  4. 4.
    Cabell CH, Jollis JG, Peterson GE, et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med. 2002;162:90–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005;293:3012–21.PubMedCrossRefGoogle Scholar
  6. 6.
    Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111:e394–434.PubMedCrossRefGoogle Scholar
  7. 7.
    McGrath BJ, Kang SL, Kaatz GW, et al. Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis. Antimicrob Agents Chemother. 1994;38:2034–40.PubMedGoogle Scholar
  8. 8.
    Watanakunakorm C, Glotzbecker C. Enhancement of the effects of anti-staphylococcal antibiotics by aminoglycosides. Antimicrob Agents Chemother. 1974;6:802–6.PubMedGoogle Scholar
  9. 9.
    Sande MA, Johnson ML. Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus. J Infect Dis. 1975;131:367–75.PubMedCrossRefGoogle Scholar
  10. 10.
    Sande MA, Courtney KB. Nafcillin–gentamicin synergism in experimental staphylococcal endocarditis. J Lab Clin Med. 1976;88:118–24.PubMedGoogle Scholar
  11. 11.
    Abrams B, Sklaver A, Hoffman T, et al. Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers. Ann Intern Med. 1979;90:789–91.PubMedGoogle Scholar
  12. 12.
    Ribera E, Gómez-Jimenez J, Cortes E, et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Ann Intern Med. 1996;125:969–74.PubMedGoogle Scholar
  13. 13.
    Watanakunakorn C, Baird IM. Prognostic factors in Staphylococcus aureus endocarditis and results of therapy with a penicillin and gentamicin. Am J Med Sci. 1977;273:133–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med. 1982;97:496–503.PubMedGoogle Scholar
  15. 15.
    Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30:633–8.PubMedCrossRefGoogle Scholar
  16. 16.
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1–266.CrossRefGoogle Scholar
  17. 17.
    Librero J, Peiró S, Ordiñana R. Chronic comorbidity and outcomes of hospital care: length of stay, mortality, and readmission at 30 and 365 days. J Clin Epidemiol. 1999;52:171–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Fowler VG Jr, Kong LK, Corey GR, et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis. 1999;179:1157–61.PubMedCrossRefGoogle Scholar
  19. 19.
    Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore). 2003;82:333–9.CrossRefGoogle Scholar
  20. 20.
    Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons; 1989.Google Scholar
  21. 21.
    Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol. 1996;49:907–16.PubMedCrossRefGoogle Scholar
  22. 22.
    Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health. 1989;79:340–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Robins JM, Greenland S. The role of model selection in causal inference from nonexperimental data. Am J Epidemiol. 1986;123:392–402.PubMedGoogle Scholar
  24. 24.
    Kreisel K, Boyd K, Langenberg P, et al. Risk factors for recurrence in patients with Staphylococcus aureus infections complicated by bacteremia. Diagn Microbiol Infect Dis. 2006;55:179–84.PubMedCrossRefGoogle Scholar
  25. 25.
    Johnson LB, Almoujahed MO, Ilg K, et al. Staphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis. 2003;35:782–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Gottlieb GS, Fowler VG Jr, Kong LK, et al. Staphylococcus aureus bacteremia in the surgical patient: a prospective analysis of 73 postoperative patients who developed Staphylococcus aureus bacteremia at a tertiary care facility. J Am Coll Surg. 2000;190:50–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Marr KA, Kong L, Fowler VG, et al. Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int. 1998;54:1684–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Raad II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 1992;14:75–82.PubMedCrossRefGoogle Scholar
  29. 29.
    Ehni WF, Reller LB. Short-course therapy for catheter-associated Staphylococcus aureus bacteremia. Arch Intern Med. 1989;149:533–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Chang FY, MacDonald BB, Peacock JE Jr, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore). 2003;82:322–32.CrossRefGoogle Scholar
  31. 31.
    Conlon PJ, Jefferies F, Krigman HR, et al. Predictors of prognosis and risk of acute renal failure in bacterial endocarditis. Clin Nephrol. 1998;49:96–101.PubMedGoogle Scholar
  32. 32.
    Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009;48:713–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • T. L. Lemonovich
    • 1
  • K. Haynes
    • 2
  • E. Lautenbach
    • 2
    • 3
    • 4
    • 5
  • V. K. Amorosa
    • 3
    • 6
  1. 1.Division of Infectious Diseases and HIV Medicine, Department of MedicineCase Western Reserve UniversityClevelandUSA
  2. 2.Department of Biostatistics and EpidemiologyUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  3. 3.Division of Infectious Diseases, Department of MedicineUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  4. 4.Centers for Education and Research on TherapeuticsUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  5. 5.Clinical Epidemiology and BiostatisticsUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  6. 6.Philadelphia Veterans Affairs Medical Center (PVAMC)PhiladelphiaUSA

Personalised recommendations